Trial Profile
A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination With CCL21 for Patients With Stage IV Adenocarcinoma of the Lung
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs CD40L GVAX (Primary) ; CCL 21
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 10 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 Dec 2017 Planned End Date changed from 28 Feb 2018 to 1 Dec 2018.